National Veterinary Institute
Fiscal Year 2016 EC (2024/2025 GC)
Revenue
ETB 364.5M
Net Profit
ETB 109.9M
Total Assets
ETB 1.3B
Total Equity
ETB 1.0B
Profit Breakdown
Key income statement items
Cash Flow Activities
Net cash from each activity
Asset Composition
Breakdown of total assets
Statement of Profit or Loss and Other Comprehensive Income
FY 2016 EC
| Item | Amount (ETB) |
|---|---|
| Revenue | |
| Revenue | 364,474,383 |
| Cost of sales | -127,202,323 |
| Gross profit | 237,272,060 |
| Other Income | |
| Other operating income | 17,854,932 |
| Gain for currency fluctuation | 27,366 |
| Total income | 255,154,357 |
| Operating Expenses | |
| General and administration expense | -97,039,436 |
| Allowance for stock loss and doubtful debts | 0 |
| Audit fee | -64,515 |
| Board fee | -356,300 |
| Total operating expenses | -97,460,251 |
| Profit | |
| Operating profit | 157,694,107 |
| Finance costs | 0 |
| Profit before tax | 157,694,107 |
| Current income tax expense | -41,975,858 |
| Profit after tax | 115,718,249 |
| Deferred tax asset/(liability) | -5,811,846 |
| Net profit for the year | 109,906,402 |
Statement of Financial Position
As at end of FY 2016 EC
| Item | Amount (ETB) |
|---|---|
| Non-Current Assets | |
| Property, plant and equipment | 722,182,873 |
| Intangible assets | 1,164,609 |
| Right of use asset - land | 3,441,248 |
| Non-current asset held for sale | 0 |
| Total non-current assets | 726,788,729 |
| Current Assets | |
| Inventories | 220,268,000 |
| Trade and other receivables | 127,952,816 |
| Advances and prepayments | 9,018,070 |
| Cash and short-term deposits | 172,064,666 |
| Total current assets | 529,303,552 |
| Total Assets | |
| Total assets | 1,256,092,281 |
| Equity | |
| Paid up capital | 640,004,058 |
| Donated capital | 685,687 |
| Capital reserve | 0 |
| Legal reserve | 9,581,305 |
| Retained earnings | 0 |
| Revaluation reserve | 358,874,376 |
| Total equity | 1,009,145,426 |
| Non-Current Liabilities | |
| Termination benefit liabilities | 4,753,409 |
| Deferred tax liabilities | 31,011,353 |
| Total non-current liabilities | 35,764,763 |
| Current Liabilities | |
| Trade and other payables | 170,128,715 |
| Other taxes and obligations | 2,232,315 |
| Profit tax payables | 38,821,061 |
| Total current liabilities | 211,182,091 |
| Total Liabilities & Equity | |
| Total liabilities | 246,946,854 |
| Total equity and liabilities | 1,256,092,281 |
Cash Flow Statement
FY 2016 EC
| Item | Amount (ETB) |
|---|---|
| Operating Activities | |
| Profit before tax | 157,694,107 |
| Depreciation | 24,321,213 |
| Amortization | 241,020 |
| Change in severance payable | -225,224 |
| Tax paid on assessment | -6,620,986 |
| State dividend paid | -48,966,268 |
| Decrease in trade and other receivables | -71,476,729 |
| Increase in inventories | 3,147,531 |
| Increase in trade and other payables | 11,473,710 |
| Withholding tax paid | -3,154,797 |
| Profit tax paid | -24,266,399 |
| Net cash from operating activities | 42,167,178 |
| Investing Activities | |
| Purchase of property, plant and equipment | -49,725,407 |
| Purchase of intangible assets | -414,000 |
| Increase in assets held for sale | -43,708 |
| Net cash used in investing activities | -50,183,114 |
| Financing Activities | |
| Donation received | 291,506 |
| Net cash from financing activities | 291,506 |
| Net Change in Cash | -7,724,429 |
| Closing Cash & Equivalents | 172,064,666 |
Audit Findings
#1 Advance collections were treated as sales and undelivered sales were recorded against cost of sales; revenue was recognized without satisfying performance obligations.
Advance collections were treated as sales and undelivered sales were recorded against cost of sales; revenue was recognized without satisfying performance obligations.
Advance collections were treated as sales and undelivered sales were recorded against cost of sales; revenue was recognized without satisfying performance obligations.
Amount: ETB 10.2M
#2 Direct and indirect costs (materials, labour and overhead) were not absorbed into inventory cost at year end; vaccines inventory was valued using opening standard costing.
Direct and indirect costs (materials, labour and overhead) were not absorbed into inventory cost at year end; vaccines inventory was valued using opening standard costing.
Direct and indirect costs (materials, labour and overhead) were not absorbed into inventory cost at year end; vaccines inventory was valued using opening standard costing.
Extracted from audited financial statements via OCR. Figures in Ethiopian Birr.